AIMS: To evaluate the expression of CD68 and kallikrein 6 in human gliomas, and investigate their prognostic significance for survival of brain cancer patients in comparison to some known prognostic markers. PATIENTS AND METHODS: Histological sections of 51 primary astrocytic tumours (11 benign, 40 malignant) were immunohistochemically stained for CD68, cathepsin B, kallikrein 6 and Ki-67. CD68 and kallikrein 6 expressions were also analyzed by real-time PCR in nine brain tumour biopsies. RESULTS: Both microglia and tumour cells expressed CD68. High CD68 and cathepsin B staining scores were significantly, more frequent in the malignant than in the benign tumours (p=0.036 and p=0.014, respectively). In contrast, the benign group presented a stronger immunoreactivity for kallikrein 6 compared with the malignant tumours (p=0.013). A CD68 staining score of tumour cells higher than 3 was a significant predictor of shorter overall survival (p<0.01) in all patients and of borderline significance in the malignant group (p=0.057). Strong CD68 staining was of greater predictive value in the subgroup of anaplastic astrocytomas (p=0.021). Furthermore, as expected on the basis of our previous studies, prognostic significance was confirmed for cathepsin B, but not for any of the other markers under evaluation. CONCLUSION: Kallikrein 6 was down-regulated in malignant glioma, but this differential expression did not have an impact on patient prognosis. In contrast, immunostaining of glioma tissue for CD68 and for cathepsin B may be used for prognosis of survival in these patients. This finding suggests that besides the known role of cathepsin B in invasion and angiogenesis, CD68 may be also associated with glioma progression.
AIMS: To evaluate the expression of CD68 and kallikrein 6 in humangliomas, and investigate their prognostic significance for survival of brain cancerpatients in comparison to some known prognostic markers. PATIENTS AND METHODS: Histological sections of 51 primary astrocytic tumours (11 benign, 40 malignant) were immunohistochemically stained for CD68, cathepsin B, kallikrein 6 and Ki-67. CD68 and kallikrein 6 expressions were also analyzed by real-time PCR in nine brain tumour biopsies. RESULTS: Both microglia and tumour cells expressed CD68. High CD68 and cathepsin B staining scores were significantly, more frequent in the malignant than in the benign tumours (p=0.036 and p=0.014, respectively). In contrast, the benign group presented a stronger immunoreactivity for kallikrein 6 compared with the malignant tumours (p=0.013). A CD68 staining score of tumour cells higher than 3 was a significant predictor of shorter overall survival (p<0.01) in all patients and of borderline significance in the malignant group (p=0.057). Strong CD68 staining was of greater predictive value in the subgroup of anaplastic astrocytomas (p=0.021). Furthermore, as expected on the basis of our previous studies, prognostic significance was confirmed for cathepsin B, but not for any of the other markers under evaluation. CONCLUSION:Kallikrein 6 was down-regulated in malignant glioma, but this differential expression did not have an impact on patient prognosis. In contrast, immunostaining of glioma tissue for CD68 and for cathepsin B may be used for prognosis of survival in these patients. This finding suggests that besides the known role of cathepsin B in invasion and angiogenesis, CD68 may be also associated with glioma progression.
Authors: Mario Orozco-Morales; Francisco-Javier Sánchez-García; Patricia Guevara-Salazar; Oscar Arrieta; Norma Y Hernández-Pedro; Aurora Sánchez-García; Rodolfo Perez-Madrigal; Edgar Rangel-López; Benjamín Pineda; Julio Sotelo Journal: J Cancer Res Clin Oncol Date: 2011-09-27 Impact factor: 4.553
Authors: Grant W Simmons; Winnie W Pong; Ryan J Emnett; Crystal R White; Scott M Gianino; Fausto J Rodriguez; David H Gutmann Journal: J Neuropathol Exp Neurol Date: 2011-01 Impact factor: 3.685
Authors: Dimitry A Chistiakov; Murry C Killingsworth; Veronika A Myasoedova; Alexander N Orekhov; Yuri V Bobryshev Journal: Lab Invest Date: 2016-11-21 Impact factor: 5.662
Authors: Kristen L Drucker; Alex R Paulsen; Caterina Giannini; Paul A Decker; Sachiko I Blaber; Michael Blaber; Joon H Uhm; Brian P O'Neill; Robert B Jenkins; Isobel A Scarisbrick Journal: Neuro Oncol Date: 2013-01-10 Impact factor: 12.300
Authors: Johanna Klughammer; Barbara Kiesel; Thomas Roetzer; Nikolaus Fortelny; Amelie Nemc; Karl-Heinz Nenning; Julia Furtner; Nathan C Sheffield; Paul Datlinger; Nadine Peter; Martha Nowosielski; Marco Augustin; Mario Mischkulnig; Thomas Ströbel; Donat Alpar; Bekir Ergüner; Martin Senekowitsch; Patrizia Moser; Christian F Freyschlag; Johannes Kerschbaumer; Claudius Thomé; Astrid E Grams; Günther Stockhammer; Melitta Kitzwoegerer; Stefan Oberndorfer; Franz Marhold; Serge Weis; Johannes Trenkler; Johanna Buchroithner; Josef Pichler; Johannes Haybaeck; Stefanie Krassnig; Kariem Mahdy Ali; Gord von Campe; Franz Payer; Camillo Sherif; Julius Preiser; Thomas Hauser; Peter A Winkler; Waltraud Kleindienst; Franz Würtz; Tanisa Brandner-Kokalj; Martin Stultschnig; Stefan Schweiger; Karin Dieckmann; Matthias Preusser; Georg Langs; Bernhard Baumann; Engelbert Knosp; Georg Widhalm; Christine Marosi; Johannes A Hainfellner; Adelheid Woehrer; Christoph Bock Journal: Nat Med Date: 2018-08-27 Impact factor: 53.440
Authors: Eduardo Martínez-Morillo; Anastasia Diamandis; Alexander D Romaschin; Eleftherios P Diamandis Journal: PLoS One Date: 2012-09-25 Impact factor: 3.240